Shirish Agarwal
speaker
10,336 appearances
81 recordings
1 series
first heard May 2026
last heard 4 Aug
Shirish Agarwal’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 81 in all, peaking in Jun 2026 with 40.
Appearances
Well, that brings us to what each side actually brings to the table to build that infrastructure.
We have two very distinct corporate profiles here.
AstraZeneca, which trades under the ticker AZN, has built a very strong growth profile primarily around its cancer drugs and rare disease treatments.
So you combine the internal growth profile of AZN with the vast commercial distribution network of BMY.
But the material points out immediate hurdles to combining those pipelines.
Specifically, it points to distracted management.
Is that a real tangible risk or just a convenient excuse?
I mean, these are massive global corporations with thousands of executives.
Surely they can walk and chew gum at the same time.
Which takes years, right?
I see.
That makes total sense.
Then you add the regulatory obstacles on top of that, specifically regarding antitrust concerns in the oncology space.
AstraZeneca has a drug called Mfinzi, and Briscoe-Myers Squibb has a drug called Opdivo.
They compete directly against each other in the cancer immunotherapy market.
For those unfamiliar with the medical phrasing, immunotherapy is a treatment that uses a person's own immune system to fight cancer.
So going back to analogies, this antitrust concern is exactly like two rival sports teams merging and suddenly realizing they both have top-tier starting quarterbacks.
You have Infanzia on one side, Opdivo on the other.
OK, indications.
So they are fighting for the exact same patients.
Showing 21–40 of 10,336 · page 2 of 517
← Previous
Next →